STOCK TITAN

OneMedNet SEC Filings

ONMD NASDAQ

Welcome to our dedicated page for OneMedNet SEC filings (Ticker: ONMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

The OneMedNet Corporation (NASDAQ: ONMD) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into OneMedNet’s corporate governance, capital structure, and public company obligations as it operates its iRWD™ Real-World Data platform and related services.

Among the key documents, investors can review OneMedNet’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s business, risk factors, and financial condition. Definitive proxy statements on Schedule 14A, such as the 2025 proxy, outline matters submitted to stockholders, including director elections, auditor ratification, and information about the annual meeting format and voting procedures. These materials also explain how stockholders of record and beneficial owners can participate in the company’s virtual annual meetings.

Current reports on Form 8-K are particularly important for tracking material events affecting ONMD. In 2025, for example, OneMedNet filed 8-Ks describing Nasdaq listing compliance updates related to the minimum bid price and market value of listed securities requirements, as well as board-related matters. Such filings help investors understand how the company is addressing exchange listing standards and corporate governance changes.

On Stock Titan, OneMedNet’s filings are updated as new documents are posted to the SEC’s EDGAR system. AI-powered summaries can assist readers by highlighting the main points of lengthy filings, such as changes in listing status, significant agreements, or governance proposals, while links to specific forms—10-K, 10-Q, 8-K, and DEF 14A—allow deeper review of the underlying disclosures.

Rhea-AI Summary

OneMedNet Corporation will hold its 2025 Annual Meeting on December 17, 2025 at 11:00 a.m. CT via live audio webcast at https://www.cstproxy.com/onemednet/2025. Stockholders will vote to elect two Class II directors for three-year terms and to ratify WithumSmith+Brown, PC as independent auditor for 2025.

Holders of record on October 23, 2025 may vote; there were 51,157,069 shares of common stock outstanding as of that date. The Board recommends voting FOR both director nominees and FOR auditor ratification. Director Jair Clarke will not stand for re-election; the Board size will be reduced to eight after the meeting.

The Audit Committee reports Withum fees of $840,000 for 2024 (including $790,000 audit and $50,000 tax). BF Borgers was dismissed in May 2024 following an SEC order; its 2023 report included a going concern explanatory paragraph and noted material weaknesses, with no disagreements reported.

Executive updates include RSU awards to leadership and related-party financings and conversions in 2025 involving Dr. Thomas Kosasa and Dr. Jeffrey Yu. As of October 23, 2025, beneficial ownership includes Dr. Kosasa at 30.8% and Dr. Yu at 13.8%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
proxy
-
Rhea-AI Summary

OneMedNet Corporation announced that director Jair Clarke will not stand for re-election at the Company’s 2025 Annual Meeting of Stockholders. The Company stated his decision was not due to any disagreement with the Company or management. Mr. Clarke will remain on the Board until the Annual Meeting and will continue to serve in an advisory capacity thereafter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

OneMedNet Corporation reported that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq staff notified the company that, for 10 consecutive business days from September 24, 2025 through October 7, 2025, the closing bid price of its common stock was at least $1.00 per share, satisfying Nasdaq Listing Rule 5550(a)(2). With this notice, the prior bid price deficiency has been resolved and the listing compliance matter is now closed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Summary

OneMedNet Corporation has regained compliance with Nasdaq’s continued listing standards. The company previously received a notice on March 12, 2025 stating that its market value of listed securities had fallen below the required $35,000,000 threshold under Nasdaq Listing Rule 5550(b)(2).

Nasdaq staff has now notified OneMedNet that for 10 consecutive business days, from August 27, 2025 to September 10, 2025, the company’s market value of listed securities was at or above $35,000,000. As a result, OneMedNet is again in compliance with Nasdaq Listing Rule 5550(b)(2), and Nasdaq considers the matter closed, allowing its common stock and warrants to remain listed on The Nasdaq Capital Market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of OneMedNet (ONMD)?

The current stock price of OneMedNet (ONMD) is $0.8657 as of March 13, 2026.

What is the market cap of OneMedNet (ONMD)?

The market cap of OneMedNet (ONMD) is approximately 40.0M.

ONMD Rankings

ONMD Stock Data

40.00M
14.67M
Health Information Services
Services-commercial Physical & Biological Research
Link
United States
SURREY

ONMD RSS Feed